Article

Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution

Broad Institute, Cambridge, Massachusetts, USA.
Nature Methods (Impact Factor: 25.95). 02/2010; 7(2):133-6. DOI: 10.1038/nmeth.1414
Source: PubMed

ABSTRACT Bisulfite sequencing measures absolute levels of DNA methylation at single-nucleotide resolution, providing a robust platform for molecular diagnostics. We optimized bisulfite sequencing for genome-scale analysis of clinical samples: here we outline how restriction digestion targets bisulfite sequencing to hotspots of epigenetic regulation and describe a statistical method for assessing significance of altered DNA methylation patterns. Thirty nanograms of DNA was sufficient for genome-scale analysis and our protocol worked well on formalin-fixed, paraffin-embedded samples.

1 Follower
 · 
186 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the past decade, epigenetic mechanisms and their modulation by dietary agents have gained major interest in the cancer prevention and nutrition community. Gene expression is epigenetically regulated by DNA methylation, histone tail modifications, and non-coding (micro) RNAs. Given the fact that epigenetic aberrations are reversible and represent potentially initiating events in the development of diseases, they have been identified as promising new targets for prevention strategies. Evidence is accumulating that dietary cancer chemopreventive agents from various sources, including green tea, soy, turmeric, broccoli, and other fruit and vegetables, can modulate DNA methylation, at least in vitro. To facilitate in vivo studies with focus on genome-wide modulation of DNA methylation, we here give an overview on current affinity enrichment- and bisulfite treatment-based methodologies for methylation profiling that might be useful for rodent models and human intervention studies. We also summarize genome-wide methylome analyses performed with dietary agents in vitro and in vivo and conclude with some practical considerations for the design of future dietary intervention studies.
    02/2015; 1(1):31-45. DOI:10.1007/s40495-014-0001-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods for single-cell genome and transcriptome sequencing have contributed to our understanding of cellular heterogeneity, whereas methods for single-cell epigenomics are much less established. Here, we describe a whole-genome bisulfite sequencing (WGBS) assay that enables DNA methylation mapping in very small cell populations (μWGBS) and single cells (scWGBS). Our assay is optimized for profiling many samples at low coverage, and we describe a bioinformatic method that analyzes collections of single-cell methylomes to infer cell-state dynamics. Using these technological advances, we studied epigenomic cell-state dynamics in three in vitro models of cellular differentiation and pluripotency, where we observed characteristic patterns of epigenome remodeling and cell-to-cell heterogeneity. The described method enables single-cell analysis of DNA methylation in a broad range of biological systems, including embryonic development, stem cell differentiation, and cancer. It can also be used to establish composite methylomes that account for cell-to-cell heterogeneity in complex tissue samples. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal DNA methylation is known as playing an important role in the tumorgenesis. It is helpful for distinguishing the specificity of diagnosis and therapeutic targets for cancers based on characteristics of DNA methylation patterns across cancers. High throughput DNA methylation analysis provides the possibility to comprehensively filter the epigenetics diversity across various cancers. We integrated whole-genome methylation data detected in 798 samples from seven cancers. The hierarchical clustering revealed the existence of cancer-specific methylation pattern. Then we identified 331 differentially methylated genes across these cancers, most of which (266) were specifically differential methylation in unique cancer. A DNA methylation correlation network (DMCN) was built based on the methylation correlation between these genes. It was shown the hubs in the DMCN were inclined to cancer-specific genes in seven cancers. Further survival analysis using the part of genes in the DMCN revealed high-risk group and low-risk group were distinguished by seven biomarkers (PCDHB15, WBSCR17, IGF1, GYPC, CYGB, ACTG2, and PRRT1) in breast cancer and eight biomarkers (ZBTB32, OR51B4, CCL8, TMEFF2, SALL3, GPSM1, MAGEA8, and SALL1) in colon cancer, respectively. At last, a protein-protein interaction network was introduced to verify the biological function of differentially methylated genes. It was shown that MAP3K14, PTN, ACVR1 and HCK sharing different DNA methylation and gene expression across cancers were relatively high degree distribution in PPI network. The study suggested that not only the identified cancer-specific genes provided reference for individual treatment but also the relationship across cancers could be explained by differential DNA methylation.
    PLoS ONE 10(3):e0120361. DOI:10.1371/journal.pone.0120361 · 3.53 Impact Factor

Full-text (2 Sources)

Download
32 Downloads
Available from
May 27, 2014